Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade D 309.8 0.24% 0.74
BIIB closed up 0.24 percent on Wednesday, November 22, 2017, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical BIIB trend table...

Date Alert Name Type % Chg
Nov 22 NR7 Range Contraction 0.00%
Nov 22 Bollinger Band Squeeze Range Contraction 0.00%
Nov 21 Bollinger Band Squeeze Range Contraction 0.24%
Nov 20 Bollinger Band Squeeze Range Contraction 0.11%
Nov 20 MACD Bearish Signal Line Cross Bearish 0.11%
Nov 17 MACD Bullish Signal Line Cross Bullish -1.33%
Nov 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.33%
Nov 10 Doji - Bullish? Reversal -0.21%
Nov 8 NR7 Range Contraction -0.89%
Nov 8 Narrow Range Bar Range Contraction -0.89%

Older signals for BIIB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 348.84
52 Week Low 244.28
Average Volume 1,259,457
200-Day Moving Average 288.5559
50-Day Moving Average 319.467
20-Day Moving Average 311.7955
10-Day Moving Average 311.218
Average True Range 6.6222
ADX 20.72
+DI 16.38
-DI 24.11
Chandelier Exit (Long, 3 ATRs ) 301.2434
Chandelier Exit (Short, 3 ATRs ) 321.6766
Upper Bollinger Band 317.2125
Lower Bollinger Band 306.3785
Percent B (%b) 0.32
BandWidth 3.474713
MACD Line -2.7358
MACD Signal Line -2.6144
MACD Histogram -0.1214
Fundamentals Value
Market Cap 65.51 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 20.33
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 315.74
Resistance 3 (R3) 315.52 313.31 314.75
Resistance 2 (R2) 313.31 311.80 313.43 314.42
Resistance 1 (R1) 311.56 310.87 312.44 311.78 314.09
Pivot Point 309.35 309.35 309.79 309.47 309.35
Support 1 (S1) 307.60 307.84 308.48 307.82 305.51
Support 2 (S2) 305.39 306.91 305.51 305.18
Support 3 (S3) 303.64 305.39 304.85
Support 4 (S4) 303.86